share_log

Neogen Analyst Ratings

Benzinga Analyst Ratings ·  Oct 10, 2022 10:02
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/10/2022 12.99% Piper Sandler $20 → $14 Maintains Neutral
08/30/2022 61.42% Piper Sandler $26 → $20 Maintains Neutral
08/01/2022 109.85% Piper Sandler $25 → $26 Maintains Neutral
07/12/2022 101.78% Piper Sandler → $25 Initiates Coverage On → Neutral
02/10/2020 610.25% Stephens & Co. → $88 Reinstates → Overweight
03/19/2019 Craig-Hallum Upgrades Hold → Buy
03/27/2018 424.62% Stephens & Co. $62 → $65 Maintains Equal-Weight

Neogen Questions & Answers

What is the target price for Neogen (NEOG)?

The latest price target for Neogen (NASDAQ: NEOG) was reported by Piper Sandler on October 10, 2022. The analyst firm set a price target for $14.00 expecting NEOG to rise to within 12 months (a possible 12.99% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Neogen (NEOG)?

The latest analyst rating for Neogen (NASDAQ: NEOG) was provided by Piper Sandler, and Neogen maintained their neutral rating.

When is the next analyst rating going to be posted or updated for Neogen (NEOG)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neogen was filed on October 10, 2022 so you should expect the next rating to be made available sometime around October 10, 2023.

Is the Analyst Rating Neogen (NEOG) correct?

While ratings are subjective and will change, the latest Neogen (NEOG) rating was a maintained with a price target of $20.00 to $14.00. The current price Neogen (NEOG) is trading at is $12.39, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment